Skip to main content
Signal8

Evelo Biosciences, Inc. (EVLO)

Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.

Sector: Biotechnology

Industry: Biotechnology

Evelo Biosciences, Inc. logo

Evelo Biosciences, Inc.

OTC:EVLOHealthcare
CLOSED
Mkt Cap-
EV-
Float18.9M
O/S37.97M
VOL1K sh
$ Vol$0
RVOL1.00×
Inst Own-
SI<0.1%
Net Cash/Sh-$0.08
EarningsNov 17 · Today
Dilution
Financials Summary
Revenue$0
Net Income-$114.53M
Total Assets$64.44M
Free Cash Flow-$101.86M
Debt & Equity
Debt 111%
Total Debt$51.14M
Total Equity-$4.99M
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
  1. 1:20Reverse split
    Jun 30, 202320 shares → 1
  2. 1:100Reverse split
    Jun 29, 2006100 shares → 1
Balance Sheet Details
Assets$64.44M
Liabilities$69.43M
Accounts Receivable$0
Accounts Payable$1.76M
Inventory$0
PP&E (Net)$11.71M
Goodwill$0
Intangible Assets$0
Income Statement
PeriodFY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$0$0$0$0$0$0
YoY Growth-------
Cost of Revenue$0$0$0$0$0$0$0
Gross Profit$0$0$0$0$0$0$0
Gross Margin-------
Research and Development$78.55M$83.64M$69.62M$63.13M$39.88M$19.96M$9.13M
Selling, General, and Administrative$29.91M$31.75M$22.27M$23.23M$18.22M$7.57M$3.89M
Other$0$0$0$0$0$0-$20K
Total Operating Expenses$108.47M$115.4M$91.89M$86.36M$58.1M$27.53M$13.03M
Operating Income (EBIT)-$108.47M-$115.4M-$91.89M-$86.36M-$58.1M-$27.53M-$13.03M
Operating Margin-------
Interest Expense$4.67M$3.61M$2.11M$1.05M$1.56M$0$0
Interest Income$5K$4K$0$1K$0$0$0
Other Income (Expense)-$5.13M-$6.35M-$1.37M$885K$1.16M-$516K-$307K
Income Before Tax (EBT)-$113.6M-$121.75M-$93.26M-$85.47M-$56.95M-$28.05M-$13.33M
Income Tax Expense$930K$428K$409K$190K-$3.09M$215K$0
Net Income-$114.53M-$122.18M-$93.67M-$85.66M-$53.85M-$28.05M-$13.33M
Net Income Margin-------
Supplementary Data
EPS-26.28-46.18-47.45-53.49-49.25-149.98-94.55
Diluted EPS-26.28-46.18-47.45-53.49-49.25-149.55-94.06
Weighted Average OS4.36M2.65M1.97M1.60M1.09M187,000141,000
EBITDA-$106.34M-$115.4M-$89.86M-$82.66M-$53.45M$834K$495K
EBITDA Margin-------
Balance Sheet
PeriodFY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Assets
Current Assets
Cash and Cash Equivalents$47.94M$68.44M$68.86M$77.83M$147.92M$38.25M$15.54M
Short-Term Investments$0$0$0$0$0$0$0
Cash and Short-Term Investments$47.94M$68.44M$68.86M$77.83M$147.92M$38.25M$15.54M
Accounts Receivable$0$0$0$0$0$0$0
Inventory$0$0$0$0$0$0$0
Other Current Assets$3.63M$0$250K-$3.18M$0$0$0
Total Current Assets$51.57M$71.03M$70.98M$77.83M$147.92M$38.78M$15.72M
Long-Term Assets
Property, Plant & Equipment Net$11.71M$15.53M$18.23M$8.34M$6.92M$3.5M$2.5M
Goodwill$0$0$0$0$0$0$0
Intangible Assets$0$0$0$0$0$0$0
Long-Term Investments$0$0$0$0$0$0$0
Deferred Tax Assets$0$0$0$0$0$0$0
Other Long-Term Assets$1.16M$1.31M$3.55M$4.75M$5.02M$1.51M$346K
Total Long-Term Assets$12.87M$16.84M$21.78M$13.09M$11.95M$5.01M$2.85M
Other Assets$0$0$0$0$0$0$0
Total Assets$64.44M$87.87M$90.64M$90.92M$159.87M$43.79M$18.57M
Liabilities
Current Liabilities
Accounts Payable$1.76M$1.6M$1.44M$620K$1.52M$1.41M$637K
Short-Term Debt$0$1.95M$0$0$0$0$0
Current Income Tax Payable$0$0$0$0$0$0$0
Current Unearned Revenue$0$13.07M$0$0$0$0$0
Other Current Liabilities$1.62M$742K$7.76M$9.12M$7.72M$2.43M$300K
Total Current Liabilities$12.39M$17.36M$19.83M$9.74M$9.23M$3.84M$2.25M
Long-Term Liabilities
Long-Term Debt$43.61M$46.56M$30.05M$19.63M$12.3M$9.97M$9.93M
Long-Term Unearned Revenue$7.5M$7.5M$0$0$0$0$0
Long-Term Deferred Tax Liabilities$0$0$0$0$0$0$0
Other Long-Term Liabilities$659K$7.5M$284K$1.35M$1.38M$580K$865K
Total Long-Term Liabilities$57.04M$61.84M$40.32M$20.98M$13.68M$10.55M$10.8M
Other Liabilities$0$0$0$0$0$0$0
Total Liabilities$69.43M$79.2M$60.15M$30.72M$22.92M$14.38M$13.04M
Stockholders' Equity
Preferred Stock$0$0$0$90.92M$0$84K$33.86M
Common Stock$111K$54K$47K$32K$32K$20K$4K
Retained Earnings-$529.22M-$414.69M-$292.52M-$198.85M-$113.38M-$56.41M-$28.34M
Comprehensive Income & Other$0$0$0-$90.92M-$18K-$1.43M-$595K
Other Stockholders' Equity$524.12M$423.31M$322.96M$259.02M$250.3M$85.79M$33.86M
Total Equity-$4.99M$8.67M$30.48M$60.2M$136.95M$29.4M$5.53M
Minority Interest$0$0$0$0$0$0$0
Total Liabilities and Equity$64.44M$87.87M$90.64M$90.92M$159.87M$43.79M$18.57M
Supplementary Data
Total Debt$51.14M$56.29M$40.04M$19.63M$12.3M$9.97M$9.93M
Net Debt$3.2M-$12.15M-$28.82M-$58.2M-$135.61M-$28.28M-$5.61M
Cash Flow Statement
PeriodFY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
CurrencyUSDUSDUSDUSDUSDUSDUSD
Period Ending2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating Activities
Net Income-$114.53M-$122.18M-$93.67M-$85.47M-$56.95M-$28.05M-$13.33M
Depreciation & Amortization$2.06M$2.22M$2.03M$1.76M$1.94M$834K$495K
Deferred Income Tax$0$3.22M-$6K-$166K$406K$301K$20K
Stock-Based Compensation$15.16M$15.85M$8.47M$8.16M$6.06M$1.54M$419K
Changes in Working Capital:
  Accounts Receivable$0$0$0$0$0$0$0
  Inventory$0$0$0$0$0$0$0
  Accounts Payable$170K$159K$837K-$585K-$221K$774K-$43K
  Other Working Capital-$9.84M$1.91M$6.93M$4.06M$1.39M$1.3M$99K
Total Working Capital Change-$9.67M$2.07M$7.76M$3.47M$1.16M$2.07M$56K
Other Non-Cash Items$5.74M$2.1M$2.35M$255K$103K$35K$28K
Net Cash from Operating-$101.23M-$96.72M-$73.06M-$71.98M-$47.28M-$23.27M-$12.31M
Investing Activities
Capital Expenditures-$622K-$1.52M-$1.32M-$3.03M-$5.46M-$1.74M-$1.25M
Acquisitions$0$0$0$0$0$0$10.49M
Purchases of Investments$0$0$0$0-$136.09M$0$0
Sales of Investments$0$0$0$55M$81.25M$0$0
Other Investing Activities$0$38K$6K$2K$171K$0$27K
Net Cash from Investing-$622K-$1.48M-$1.31M$51.97M-$60.13M-$1.74M$9.26M
Financing Activities
Debt Repaid$3.12M-$14.78M-$10M-$4.48M-$4.97M--$7M
Common Stock Issuance$84.54M$81.75M$54.99M$0$75.83M$0$0
Common Stock Repurchases$0$0$0$0$0$0$0
Dividends Paid$0$0$0$0$0$0$0
Other Financing Activities$234K$1.01M$471K$511K-$128K$64K$1.25M
Net Cash from Financing$81.66M$97.54M$65.47M$4.99M$162.01M$48.97M$15.74M
Forex Effect-$454K$0$0$0$0$0$0
Net Change in Cash-$20.66M-$666K-$8.91M-$15.02M$54.6M$23.96M$12.69M
Supplementary Data
Operating Cash Flow-$101.23M-$96.72M-$73.06M-$71.98M-$47.28M-$23.27M-$12.31M
Capital Expenditure-$622K-$1.52M-$1.32M-$3.03M-$5.46M-$1.74M-$1.25M
Free Cash Flow-$101.86M-$98.24M-$74.38M-$75.01M-$52.74M-$25.01M-$13.56M
Cash at Beginning$69.75M$70.42M$79.33M$94.35M$39.75M$15.79M$3.1M
Cash at End$49.1M$69.75M$70.42M$79.33M$94.35M$39.75M$15.79M